Publications by authors named "John Alam"

Claim this Profile
I
Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease.
Dominique Gouilly, Alexandre Da-Costa, Agathe Vrillon, Aurélie Pistono, Marie Goubeaud, John Alam, Claire Thalamas

J Neuroinflammation· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspective: Minimally clinically important "symptomatic" benefit associated with disease modification resulting from anti-amyloid immunotherapy.
John Alam, Marwan N Sabbagh

Alzheimers Dement (N Y)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.
John J Alam, Ralph A Nixon

Mol Neurodegener· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
John J Alam, Paul Maruff, Susan R Doctrow, Hui-May Chu, Jennifer Conway

Neurology· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.
John J Alam, Ralph A Nixon

Mol Neurodegener· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.
Ying Jiang, John J Alam, Stephen N Gomperts, Paul Maruff, Afina W Lemstra, Sandeep Malampati

Nat Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying pharmacological approaches to correcting basal forebrain cholinergic neuronal (BFCN) dysfunction and degeneration.
John J Alam, Ralph A Nixon

Neuropsychopharmacology· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
Niels D Prins, John E Harrison, Hui-May Chu, Kelly Blackburn, John J Alam

Alzheimers Res Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level.
John J Alam, Michael Krakovsky, Ursula Germann, Aharon Levy

PLoS One· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P38α MAPK Signaling-A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease.
Ursula A Germann, John J Alam

Int J Mol Sci· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An exploratory clinical study of p38 kinase inhibition in Alzheimer's disease.
Philip Scheltens, Niels Prins, Adriaan Lammertsma, Maqsood Yaqub, Alida Gouw, John Alam

Ann Clin Transl Neurol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting neuronal MAPK14/p38α activity to modulate autophagy in the Alzheimer disease brain.
John Alam, Wiep Scheper

Autophagy· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats.
John J Alam

J Alzheimers Dis· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming obstacles to repurposing for neurodegenerative disease.
Diana W Shineman, John Alam, Margaret Anderson, Sandra E Black, Aaron J Carman

Ann Clin Transl Neurol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.
Bambang S Adiwijaya, Tara L Kieffer, Joshua Henshaw, Karen Eisenhauer, Holly Kimko, John J Alam

PLoS Comput Biol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Vinod K Rustgi, William M Lee, Eric Lawitz, Stuart C Gordon, Nezam Afdhal, John Alam

Hepatology· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
John G McHutchison, Gregory T Everson, Stuart C Gordon, Ira M Jacobson, Mark Sulkowski, John Alam

N Engl J Med· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko, Peter Ferenci, Stanislas Pol, John Alam

N Engl J Med· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Senator John McCain and risk of melanoma-associated mortality.
John Alam

Lancet· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
Patrick Marcellin, Yves Horsmans, Frederik Nevens, Jean-Didier Grange, Jean-Pierre Bronowicki, John Alam

J Hepatol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.
Hendrik W Reesink, Stefan Zeuzem, Christine J Weegink, Nicole Forestier, Andre van Vliet, John Alam

Gastroenterology· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
John G McHutchison, Mitchell L Shiffman, Ramsey C Cheung, Stuart C Gordon, Teresa L Wright, John Alam

Antivir Ther· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apoptosis: target for novel drugs.
John J Alam

Trends Biotechnol· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis